MedTrace Logo

RN624 For Pain Of Post-Herpetic Neuralgia

NCT00568321 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2021-05-28

Study results available
· View outcomes & findings →

Summary

This study will test the efficacy and safety of two doses levels of RN624 versus placebo for the relief of pain caused by post-herpetic neuralgia (PHN).

Conditions

  • Neuralgia, Postherpetic

Interventions

DRUG

RN624

50 mcg/kg

DRUG

RN624

200 mcg/kg

DRUG

Placebo

placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-19
Primary Completion
2008-12-20
Completion
2009-01-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00568321 on ClinicalTrials.gov